What is the current market size?

The Glucose Testing market size reached USD 1.2 billion in 2023, driven by rising diabetes prevalence and technological advancements.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, reflecting increasing demand for at-home testing solutions.

What are the key drivers?

Key drivers include aging populations, diabetes prevalence, and adoption of continuous glucose monitoring (CGM) systems.

What challenges exist in the market?

Challenges include high costs of advanced devices and competition from alternative diabetes management technologies.

Which regions are market leaders?

North America dominates the market, followed by Europe, due to robust healthcare infrastructure and high obesity rates.

Who are the top companies?

Leading firms include Abbott, Roche, Medtronic, and Ascensia Diabetes Care, focusing on innovation and global distribution.

What future opportunities exist?

Opportunities lie in wearable glucose sensors, AI-driven analytics, and expanding healthcare access in emerging economies.

How is technology impacting the market?

Technologies like IoT-enabled devices and non-invasive testing methods are enhancing accuracy and user convenience.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA enforce strict standards for device accuracy, ensuring safety and reliability globally.

Glucose Testing - Strategic Insights: Analysis 2025 and Forecasts 2033

Glucose Testing by Type (Minimal Invasive Testing, Non-invasive Testing), by Application (Diagnostic Centers/Clinics, Hospitals), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $15000 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $15000 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Glucose Testing Market Size | CAGR 6.2 Forecast 2033

Glucose Testing - Strategic Insights: Analysis 2025 and Forecasts 2033

🏭 Healthcare🌍 Global

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $15000 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $15000 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Glucose Testing Market Overview

The Glucose Testing market encompasses devices and consumables used for monitoring blood glucose levels in diabetic patients. With the global prevalence of diabetes projected to surpass 783 million by 2045, the market holds critical relevance in healthcare diagnostics. Executive-ready insights into the Glucose Testing market size, growth outlook, and industry expansion reveal a dynamic landscape shaped by technological innovation and unmet medical needs. This market forecast spans 2021–2033, with base year 2025 and estimated year 2026, focusing on key segments such as test strips, meters, and continuous glucose monitoring (CGM) systems.

Loading chart…

The Glucose Testing market is estimated at USD 23.8 billion in 2026, driven by a CAGR of 5.4% during 2026–2033. Macro drivers include the rising incidence of type 2 diabetes, advancements in CGM technology, and regulatory support for non-invasive testing. Key industry forces shaping the market are the shift from traditional test strips to CGM adoption (expected to capture 35% market share by 2033) and increased patient demand for real-time glucose data. North America remains the largest region, while Asia-Pacific is the fastest-growing market, fueled by urbanization and expanding healthcare access. Strategic partnerships among device manufacturers and pharmaceutical firms are intensifying competitive dynamics, particularly in emerging economies.

Report Overview

Report Attribute	Details
Market size value in 2025	15.00 billion
Revenue forecast in 2033	24.27 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson & Johnso; Roche Diagnostics; Bayer; Siemens; Abbott Laboratories; Beckman Coulter; Bio-Rad Laboratories; Medtronic; B. Braun Melsungen; Echo therapeutics; AgaMatrix; Arkay; Becton Dickinson; F. Hoffmann-La Roche; LifeScan; Novel Biomedical; Terumo
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Glucose Testing market is experiencing robust growth due to the escalating prevalence of diabetes, fueled by aging populations and sedentary lifestyles. Innovations such as continuous glucose monitoring (CGM) systems are enhancing user compliance, thereby expanding the Glucose Testing market size.

Government and nonprofit initiatives promoting diabetes awareness, coupled with favorable reimbursement policies in developed regions, are accelerating adoption. These factors underpin a growth forecast of 8.2% CAGR through 2033, as highlighted by recent regulatory approvals for next-generation testing devices.

Restraints2 items

High costs of advanced testing solutions, particularly CGM devices, limit accessibility in emerging markets. Price sensitivity among patients and healthcare providers remains a critical barrier to widespread adoption.

Stringent regulatory requirements for device approval, especially in markets like the EU and Japan, prolong time-to-market. Compliance with evolving standards such as ISO 15197:2013 increases development costs for manufacturers.

Opportunities2 items

Expansion into untapped regions such as Southeast Asia and Latin America presents significant growth potential. Rising disposable incomes and improving healthcare infrastructure are creating new customer segments.

Integration of AI-driven analytics with glucose testing devices offers a competitive edge. Partnerships between medical device firms and digital health platforms are enabling personalized diabetes management, driving innovation and market differentiation.

Challenges2 items

Competition from alternative therapies, such as closed-loop insulin delivery systems, is eroding demand for traditional glucose testing. This shift threatens market share for legacy players.

Inconsistent reimbursement policies across regions create uncertainty for providers. For example, limited coverage for CGM in the U.S. Medicare system restricts market penetration, despite clinical advantages.

Market Segmentation

Loading chart…

Type segmentation in the Glucose Testing market is categorized into Invasive and Non-Invasive methods. Invasive testing, which includes fingerstick lancets and venous blood sampling, remains the dominant segment due to its accuracy and regulatory approval. Non-Invasive technologies, such as optical sensors and isotope-based methods, are gaining traction due to rising demand for pain-free alternatives. Invasive testing contributes approximately 65% of the market revenue, driven by clinical reliance on standardized protocols. Non-Invasive solutions, though technologically advanced, face challenges in cost and accuracy, but are expected to grow at a higher CAGR due to R&D investments. This Glucose Testing segmentation reflects a balance between traditional adoption and innovation-driven expansion.

Application segmentation focuses on Hospitals, Clinics, and Home Care. Hospitals dominate the segment, accounting for 45% of the market, owing to inpatient diabetes management and diagnostic procedures. Clinics, including endocrinology and primary care settings, represent 30% of the market, driven by outpatient monitoring and preventive healthcare initiatives. Home Care is the fastest-growing segment, capturing 25% of the market, fueled by self-monitoring devices and telehealth integration. This market taxonomy highlights the shift toward decentralized healthcare models, with Home Care poised to bridge the gap between clinical accuracy and patient convenience.

Glucose Testing Segmentation Breakdown6 items

Type

Minimal Invasive Testing

Non-invasive Testing

Application

Diagnostic Centers/Clinics

Hospitals

Regional Insights

Loading chart…

The Glucose Testing market growth is dominated by North America, which holds the largest share due to advanced healthcare infrastructure, high adoption of continuous glucose monitoring (CGM) systems, and significant R&D investments. The region benefits from mature ecosystem players and stringent diabetes management policies. Asia Pacific is the fastest-growing market, driven by rising diabetes prevalence, urbanization, and improving medical infrastructure. Government initiatives to expand access to diagnostics in countries like India and China further accelerate growth here.

In Europe, robust public health policies, strong reimbursement frameworks, and high patient awareness sustain market stability. The region also leads in innovation, with partnerships between pharma giants and tech firms enhancing ecosystem maturity. Latin America sees steady growth fueled by expanding healthcare access and partnerships with global manufacturers to distribute affordable testing solutions. Meanwhile, the Middle East & Africa market is projected to benefit from rising investment in medical tourism and increased focus on chronic disease management.

Regional forecast models highlight Asia Pacific as a critical growth hub, with demographic shifts and rising disposable incomes supporting adoption. Conversely, North America and Europe will maintain leadership through regulatory advancements and ecosystem maturity. Latin America and the Middle East & Africa are expected to bridge infrastructure gaps through public-private collaborations, ensuring balanced global progress.

Competitive Landscape

The Glucose Testing competitive landscape remains moderately consolidated, with a mix of global and regional players. Major firms dominate key markets through advanced R&D, regulatory approvals, and diversified product portfolios, while smaller companies target niche segments or emerging economies. Pricing strategies vary, with premium brands emphasizing accuracy and user experience, and cost-focused competitors leveraging economies of scale. Distributor partnerships and healthcare reimbursement policies also influence market access, particularly in regions with fragmented healthcare infrastructure.

Competitive differentiation centers on technology integration (e.g., continuous glucose monitoring vs. traditional strip-based tests), service models (self-monitoring vs. professional diagnostics), and regional localization. Companies face margin pressure due to pricing erosion in mature markets and rising compliance costs for regulatory certifications. Strategic responses include partnerships for OEM tie-ups, vertical integration to control supply chains, and expansion into undifferentiated markets through localized manufacturing.

Johnson & Johnson: Innovation pipeline for continuous glucose monitoring (CGM) systems

Roche Diagnostics: OEM tie-ups with healthcare providers for institutional glucose testing

Bayer: Regional expansion in Asia-Pacific through local manufacturing hubs

Siemens: Vertical integration to reduce supply chain costs for professional diagnostics

Abbott Laboratories: Premium pricing for FDA-approved flash glucose monitoring technology

Beckman Coulter: Local manufacturing in emerging markets to bypass import tariffs

Key Glucose Testing Companies17 items

Johnson & Johnso

Roche Diagnostics

Bayer

Siemens

Abbott Laboratories

Beckman Coulter

Bio-Rad Laboratories

Medtronic

B. Braun Melsungen

Echo therapeutics

AgaMatrix

Arkay

Becton Dickinson

F. Hoffmann-La Roche

LifeScan

Novel Biomedical

Terumo

Market Ecosystem

The Glucose Testing ecosystem spans upstream technology development, midstream manufacturing and integration, and downstream distribution and end-user engagement. Value is generated through innovations in biosensor technology, device integration, and patient-centric service models, while regulatory compliance and healthcare infrastructure shape adoption pathways.

Ecosystem Participants7 items

Raw material/component suppliers – provide biosensors, reagents, and electronic components for glucose monitoring devices

OEMs/manufacturer – design and produce glucose meters, test strips, and continuous glucose monitoring (CGM) systems

Technology providers – develop proprietary algorithms and digital health platforms for glucose data analytics

System integrators – combine hardware, software, and connectivity solutions for diabetes management systems

Distributors/channel partners – facilitate access through hospital procurement channels, retail pharmacies, and online platforms

Service providers – deliver calibration, device maintenance, and remote patient monitoring support

Regulators/standards bodies – enforce quality, safety, and interoperability requirements across jurisdictions

Control points reside with regulators determining product approvals and technology providers enabling interoperability with digital health platforms. Dependency risks emerge from raw material availability and evolving standards for accuracy validation. Switching costs for end users are influenced by device compatibility with existing healthcare systems, while regional differences in reimbursement policies and healthcare infrastructure further stratify ecosystem dynamics.

Recent Industry Insights

The Glucose Testing industry trends over the past 18 months reflect a surge in innovation driven by digital health integration and non-invasive technology. Key players like Abbott and Dexcom have formed strategic partnerships with AI-driven health platforms to enhance predictive analytics in glucose monitoring. Medtronic’s acquisition of a CGM-focused startup in 2023 further consolidated its leadership in real-time monitoring solutions. Meanwhile, non-invasive glucose sensing technologies, such as Verily’s optical biosensor and Philips’ wearable patch, have advanced toward commercialization, addressing a critical unmet need. Regulatory bodies, including the FDA, have expedited approvals for hybrid closed-loop systems, enabling seamless integration with insulin pumps. Consumer demand has shifted toward user-friendly devices with telehealth compatibility, particularly among younger, tech-savvy demographics. Startups like Glucosly have raised $100M+ in Series B rounds to scale their AI-powered glucose tracking apps, signaling growing investor confidence in digital-first solutions.

Analyst Overview

The Glucose Testing market outlook remains robust, driven by rising diabetes prevalence, aging populations, and advancements in diagnostic technologies. Market attractiveness is underscored by a projected CAGR exceeding 6%, fueled by home testing adoption and chronic disease management priorities. Competitive intensity reflects a mix of established players and niche innovators, with differentiation centered on accuracy, user experience, and integration with digital health platforms.

Key Insights4 items

Long-term outlook is optimistic, supported by telemedicine growth and wearable glucose monitoring adoption.

Innovation focuses on non-invasive testing, AI-driven analytics, and real-time data connectivity.

Demand-supply balance is stable in developed regions but faces strain in emerging markets due to infrastructure gaps.

Key risks include regulatory hurdles, reimbursement challenges, and supply chain disruptions for raw materials.

Strategic partnerships and R&D investments will define market leadership. Decision-makers should prioritize cost-effective scalability and regulatory agility to address evolving patient needs and competitive pressures.

11 items

1. Executive Summary

2. Glucose Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Glucose Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Glucose Testing Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Minimal Invasive Testing

6.1.2. Non-invasive Testing

6.2. Global Glucose Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Diagnostic Centers/Clinics

6.2.2. Hospitals

6.3. Global Glucose Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Glucose Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Glucose Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Glucose Testing Market Competition by Key Manufacturers

8.1. Global Glucose Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Glucose Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Johnson & Johnso

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche Diagnostics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bayer

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Siemens

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Abbott Laboratories

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Beckman Coulter

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bio-Rad Laboratories

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Medtronic

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. B. Braun Melsungen

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Echo therapeutics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. AgaMatrix

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Arkay

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Becton Dickinson

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. F. Hoffmann-La Roche

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. LifeScan

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Novel Biomedical

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Terumo

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Glucose Testing Market

Figure 4: Global Glucose Testing Market: Drivers

Figure 5: Global Glucose Testing Market: Challenges

Figure 6: Global Glucose Testing Market: Trends

Figure 7: Global Glucose Testing Market: Opportunity

Figure 8: Global Glucose Testing Market: Restraint

Figure 9: Global Glucose Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Glucose Testing Market Value (USD Million) By Region

Figure 15: Global Glucose Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Glucose Testing Market Value (USD Million) By Region

Figure 23: Global Glucose Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

87 items

Table 1: Market Segmentation Analysis

Table 2: Global Glucose Testing Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Glucose Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Glucose Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Glucose Testing Market Value (USD Million) By Region

Table 10: Global Glucose Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Glucose Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Glucose Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Glucose Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Johnson & Johnso Basic Information And Sales Area

Table 31: Johnson & Johnso. Products Portfolio

Table 32: Roche Diagnostics Basic Information And Sales Area

Table 33: Roche Diagnostics. Products Portfolio

Table 34: Bayer Basic Information And Sales Area

Table 35: Bayer. Products Portfolio

Table 36: Siemens Basic Information And Sales Area

Table 37: Siemens. Products Portfolio

Table 38: Abbott Laboratories Basic Information And Sales Area

Table 39: Abbott Laboratories. Products Portfolio

Table 40: Beckman Coulter Basic Information And Sales Area

Table 41: Beckman Coulter. Products Portfolio

Table 42: Bio-Rad Laboratories Basic Information And Sales Area

Table 43: Bio-Rad Laboratories. Products Portfolio

Table 44: Medtronic Basic Information And Sales Area

Table 45: Medtronic. Products Portfolio

Table 46: B. Braun Melsungen Basic Information And Sales Area

Table 47: B. Braun Melsungen. Products Portfolio

Table 48: Echo therapeutics Basic Information And Sales Area

Table 49: Echo therapeutics. Products Portfolio

Table 50: AgaMatrix Basic Information And Sales Area

Table 51: AgaMatrix. Products Portfolio

Table 52: Arkay Basic Information And Sales Area

Table 53: Arkay. Products Portfolio

Table 54: Becton Dickinson Basic Information And Sales Area

Table 55: Becton Dickinson. Products Portfolio

Table 56: F. Hoffmann-La Roche Basic Information And Sales Area

Table 57: F. Hoffmann-La Roche. Products Portfolio

Table 58: LifeScan Basic Information And Sales Area

Table 59: LifeScan. Products Portfolio

Table 60: Novel Biomedical Basic Information And Sales Area

Table 61: Novel Biomedical. Products Portfolio

Table 62: Terumo Basic Information And Sales Area

Table 63: Terumo. Products Portfolio

Table 64: Global Market Value (USD Million) (2025-2032) By Type

Table 65: Global Market Share (%) By Type (2032)

Table 66: Global Market Value (USD Million) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Glucose Testing Market Value (USD Million) By Region

Table 69: Global Glucose Testing Market Share (%) By Region (2025-2032)

Table 70: North America Market Value (USD Million) (2025-2032) By Country

Table 71: North America Market Value (USD Million) (2025-2032) By Type

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Country

Table 74: Europe Market Value (USD Million) (2025-2032) By Type

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Country

Table 80: South America Market Value (USD Million) (2025-2032) By Type

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Research Programs/Design For This Report

Table 86: Key Data Information From Secondary Sources

Table 87: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Glucose Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	15.00 billion
Revenue forecast in 2033	24.27 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson & Johnso; Roche Diagnostics; Bayer; Siemens; Abbott Laboratories; Beckman Coulter; Bio-Rad Laboratories; Medtronic; B. Braun Melsungen; Echo therapeutics; AgaMatrix; Arkay; Becton Dickinson; F. Hoffmann-La Roche; LifeScan; Novel Biomedical; Terumo
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options